Alejandro Gugliucci
Overview
Explore the profile of Alejandro Gugliucci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
1412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salim P, Gonzalez A, Ojeda A, Morales E, de Leon J, Gugliucci A, et al.
Clin Chim Acta
. 2025 Feb;
569:120159.
PMID: 39894722
No abstract available.
2.
Cortes-Salim P, Gonzalez A, Gomez-Ojeda A, Gilberto Martinez-Morales E, Carlos Barrera-de Leon J, Gugliucci A, et al.
Clin Chim Acta
. 2025 Jan;
568:120117.
PMID: 39756773
Background: Research into the mechanisms of growth control during birth and postnatal life has shown that adipose tissue regulates many physiological functions in the body by secreting adipokines. The aims...
3.
Gugliucci A
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274442
Over 50% of patients who take statins are still at risk of developing atherosclerotic cardiovascular disease (ASCVD) and do not achieve their goal LDL-C levels. This residual risk is largely...
4.
Kotani K, Sakane N, Gugliucci A
Arch Med Sci Atheroscler Dis
. 2024 Mar;
9:e16-e17.
PMID: 38434942
No abstract available.
5.
Gugliucci A
Front Endocrinol (Lausanne)
. 2024 Feb;
14:1322869.
PMID: 38303975
Since statins have had such tremendous therapeutic success over the last three decades, the field of atherosclerosis has become somewhat LDL-centric, dismissing the relevance of triglycerides (TG), particularly chylomicrons, in...
6.
Watanabe J, Kotani K, Gugliucci A
Arch Med Sci Atheroscler Dis
. 2023 Dec;
8:e71-e74.
PMID: 38089160
No abstract available.
7.
Gugliucci A
J Clin Med
. 2023 Sep;
12(17).
PMID: 37685728
The availability of sugar has expanded over the past 50 years, due to improved industrial processes and corn subsidies, particularly in the form of sweetened beverages. This correlates with a...
8.
Watanabe J, Kotani K, Iwazu Y, Gugliucci A
J Clin Med
. 2023 Aug;
12(15).
PMID: 37568524
Chronic renal failure (CRF) is associated with the development of cardiovascular disease (CVD). Paraoxonase 1 (PON1), an antioxidant enzyme, shows cardioprotective properties and has been proposed as a therapeutic marker...
9.
Gugliucci A
J Clin Med
. 2023 Jul;
12(13).
PMID: 37445434
The residual risk for arteriosclerotic cardiovascular disease after optimal statin treatment may amount to 50% and is the consequence of both immunological and lipid disturbances. Regarding the lipid disturbances, the...
10.
Gugliucci A
J Clin Med
. 2023 Jun;
12(12).
PMID: 37373684
For the past 30 years, statin therapy has been the cornerstone for the reduction in the risk of atherosclerotic cardiovascular disease (ASCVD) [...].